Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
[65] Systematic review	5493 people with COPD 8 RCTs in this analysis	Any adverse effects up to 3 years 2215/2808 (78.9%) with fluticasone plus salmeterol 2116/2685 (78.8%) with placebo	OR 1.1 for overall events 95% CI 0.96 to 1.27 P = 0.18		Not significant
[65] Systematic review	923 people with COPD 2 RCTs in this analysis	Serious adverse effects 12 months 108/462 (23%) with budesonide plus formoterol 103/461 (22%) with placebo	OR 1.06 95% CI 0.78 to 1.45 P = 0.7		Not significant
[67] RCT	445 Chinese people with COPD	Incidence of adverse effects 6 months 165/297 (56%) with salmeterol 50 micrograms plus fluticasone 500 micrograms 81/148 (55%) with placebo	Significance not assessed